logo/base Created with Sketch.
logo echosens
en
chevron Contact
English version chevron
Change region

FibroScan® Mini+ 430

The mobile non-invasive solution for liver disease management, ideal for multi-site configuration

Powered by LSM by VCTE™ and CAP™ for liver fibrosis and liver steatosis assessment.

chevron chevron
wave
See product brochures

FibroScan® Mini+ 430 is designed for multi-center sharing and remote liver patient management.

Smartly adaptable to all settings

FibroScan® Mini+ 430 is light and easy to handle (5 kg). It is a battery-powered device with a 12.1-inch touchscreen.

Winner of the Red Dot Design Award 2017 for its innovative and ergonomic design, FibroScan® Mini+ 430 is provided with airplane-compatible transport suitcase.

FibroScan® Mini+ 430 is adapted to all patient morphologies as it can be used with all probes S+, M+ and XL+. The two probe connectors allows to easily switch between probes during exam.

LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness with 3,800 international peer-reviewed publications.1

CAP™  is unique patented and validated for liver steatosis assessment2,3 with 1,130 international peer-reviewed publications.

chevron Learn more

What our users say

quote

Assessment of liver stiffness and fat by non-invasive method is a huge step forward towards better management of MASLD. It has hugely impacted the way clinicians stratify the patients, chose therapy and monitor response!

Akash Shukla | Professor & Head Department of Gastroenterology Seth GSMC & KEM Hospital Mumbai

chevron Read all testimonials
chevron chevron

FibroScan® Mini+ 430 comes with a dedicated support

From installation, to training and local support, we provide you with the highest quality of services.

chevron Learn more

1. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.

2. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.

3. Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.

FibroScan® Mini+ 430 or FibroScan® Mini 430: product name may differ depending on country.

Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.

chevron User Guides FibroScan Mini+ 430

Extend FibroScan® use

chevron Contact us